MMP-9 suppresses the infiltration and cytotoxic activity of CD8+ T cells, thereby providing support for the existence of an inhibitory tumor immune microenvironment (TIME) and resistance to PD-1 inhibitors associated with gain-of-function mutations in CTNNB1 (85). The gene discussed is MMP9; the disease is neoplasm.